AnteoTech (ASX: ADO) pushed forward its advanced battery and life sciences technologies in the March 2026 quarter, achieving key product validations and expanding its sales pipeline to record levels. The company ended the period with A$3.3 million cash and no debt following a recent A$3.5 million capital raise.
- Ultranode™ 70 and 95 silicon anode products validated by independent testing
- SiMRAX samples dispatched with early customer interest
- Life Sciences CLIA product development underway with global partner
- Sales pipelines expanded to 129 ABT and 79 LS qualified leads
- A$3.5 million capital raise settled, cash at A$3.3 million with no debt
Validation Milestones Signal Battery Tech Progress
AnteoTech’s Advanced Battery Technologies (ABT) division marked significant technical progress in the March 2026 quarter. Ultranode™ 70 silicon anode material was independently validated by Swiss battery maker Wyon AG, achieving capacity retention within 10% of AnteoTech’s benchmark in coin cell tests. Wyon’s miniature commercial cells incorporating Ultranode™ 70 are set for imminent performance testing, although completion timelines have extended beyond the quarter.
Meanwhile, Ultranode™ 95, designed to boost specific energy by 40% over graphite-based cells, cleared a critical hurdle with independent validation from the Battery Innovation Centre (BIC) in Indiana, USA. Testing in Single Layer Pouch format confirmed the product meets drone battery application standards. Multi-Layer Pouch and cylindrical cell evaluations are underway, supporting ongoing negotiations for Joint Development Agreements (JDAs) with US battery manufacturers targeting defence and drone markets.
SiMRAX Samples Spark Early Market Interest
Following a joint development deal with US-based Black Diamond Structures, AnteoTech dispatched first customer samples of SiMRAX, a hybrid product combining the Anteo X® cross-linker with Molecular Rebar® carbon nanotube dispersion technology. SiMRAX has demonstrated over 50% longer cycle life in high silicon anode cells at ultra-low CNT loadings, offering cost and performance advantages. Multiple additional sample requests have been received, reflecting growing market curiosity.
The company’s ABT portfolio now spans three complementary products; Anteo X®, SiMRAX, and Anteo S™; with manufacturing capacity of approximately 1 GWh annually from its Brisbane ISO 9001-certified facility.
Life Sciences Gains Traction with CLIA Program and Market Expansion
AnteoTech’s Life Sciences (LS) business advanced a new chemiluminescent immunoassay (CLIA) product development program with a major global life sciences company, targeting the US$13 billion CLIA market. The initial work program, funded under a shared cost arrangement, is on track for completion by fiscal year-end, with positive early results.
Supporting this, the company published a white paper demonstrating that AnteoBind™ NXT activated magnetic particles outperform the commonly used Tosyl-activated alternatives, delivering up to 1.8 times higher signal-to-blank ratios and up to six times lower antibody usage. This positions AnteoBind™ NXT as a cost-effective option for CLIA kit manufacturers.
Market engagement extended to India with participation in BioAsia 2026 and strengthened ties with the Serum Institute of India (SII), which is expected to place further orders totaling approximately A$550,000 for FY2026. Post-quarter, AnteoTech secured India-based business development services to accelerate sales conversion. Negotiations also commenced with a potential Japanese distributor amid rising market interest.
Sales Pipeline Growth and International Outreach
The company reported record sample dispatches and pipeline growth, with 129 leads in ABT and 79 in LS as of mid-April, including 30% and 40% sales-qualified leads respectively. Notably, the ABT business received positive feedback on Anteo S™ from South Korean and US battery manufacturers, a product addressing battery safety by improving separator performance and reducing thermal runaway risk.
AnteoTech’s presence at key international forums; InterBattery in South Korea and the International Battery Seminar in Florida; boosted lead generation and partner engagement. The company also advanced US market entry efforts, including import and EPA regulatory approvals and distributor engagement.
This momentum follows the company’s recent capital raise, which settled in February 2026, bringing in A$3.5 million net of costs. The funds support the structured sales and marketing initiatives that are driving pipeline expansion and customer engagement, as detailed in the recent capital raise to fuel growth.
Financial Position and Corporate Developments
AnteoTech closed the quarter with A$3.291 million in cash and no debt. Operating cash outflows of A$1.6 million reflected ongoing investment in R&D, marketing, and staffing. The company appointed Scott Waddell as Interim CFO and Company Secretary, bringing over 30 years of corporate finance experience.
Looking ahead, AnteoTech aims to convert sample evaluations into sales, progress JDAs in the drone battery sector, and expand market penetration in the US, India, South Korea, and Japan. While Wyon’s commercial cell testing timelines have slipped, the company remains focused on leveraging its growing networks to secure supply agreements.
Bottom Line?
AnteoTech’s expanding sales pipeline and independent validations mark tangible progress, but converting technical milestones into revenue remains the critical next step.
Questions in the middle?
- Will the extended timeline for Wyon’s commercial cell testing delay Ultranode™ 70 market entry?
- How quickly can AnteoTech convert its growing sample evaluations into firm sales contracts?
- What impact will US regulatory approvals and distributor arrangements have on ABT’s market penetration?